Overview

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

Status:
Not yet recruiting

Trial end date:
2024-03-31

Target enrollment:

Participant gender:

Summary

Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX15 with Daratumumab Injection in Healthy Chinese Male Subjects

Phase:

Phase 1

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

Antibodies, Monoclonal
Daratumumab